Literature DB >> 28522286

Increased proportions of functionally impaired regulatory T cell subsets in systemic sclerosis.

Emese Ugor1, Diána Simon1, Giovanni Almanzar2, Ramóna Pap1, József Najbauer1, Péter Németh1, Péter Balogh1, Martina Prelog2, László Czirják3, Tímea Berki4.   

Abstract

Treg abnormalities have been implicated in the pathogenesis of systemic sclerosis (SSc). Treg subpopulations and their cytokines, IL-10 and TGF-β in the peripheral blood of early stage SSc patients were investigated. We hypothesized that epigenetically regulated methylation of the FOXP3 promoter and enhancer regions are altered in Tregs of SSc patients, which might be involved in the T cell imbalance. CD4+CD25+Foxp3+CD127- Treg cells were significantly elevated in patients with diffuse cutaneous SSc and in patients with anti-Scl-70/RNA-Pol-III autoantibody positivity and with lung fibrosis. Increased CD62L+ Treg cells were present in all SSc subgroups. The production of immunosuppressive cytokines by both CD127- and CD62L+ Tregs was diminished. We observed reduced methylation of Treg specific FOXP3 enhancer regions, and elevated FOXP3 gene expression in active SSc cases with negative correlation in the frequency of CD62L+IL-10+ Tregs. Our data indicate an inappropriate distribution and cytokine production of Treg cells in early form SSc.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epigenetic regulation; FOXP3; IL-10; Regulatory T cells; Systemic sclerosis; TGF-β

Mesh:

Substances:

Year:  2017        PMID: 28522286     DOI: 10.1016/j.clim.2017.05.013

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  16 in total

Review 1.  Treg cells in autoimmunity: from identification to Treg-based therapies.

Authors:  Lisa Göschl; Clemens Scheinecker; Michael Bonelli
Journal:  Semin Immunopathol       Date:  2019-04-05       Impact factor: 9.623

2.  Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients.

Authors:  Lucas C M Arruda; Kelen C R Malmegrim; João R Lima-Júnior; Emmanuel Clave; Juliana B E Dias; Daniela A Moraes; Corinne Douay; Isabelle Fournier; Hélène Moins-Teisserenc; Antônio José Alberdi; Dimas T Covas; Belinda P Simões; Pauline Lansiaux; Antoine Toubert; Maria Carolina Oliveira
Journal:  Blood Adv       Date:  2018-01-23

Review 3.  Epigenetic Control of Scleroderma: Current Knowledge and Future Perspectives.

Authors:  Pei-Suen Tsou
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

Review 4.  The Pathophysiological Roles of Regulatory T Cells in the Early Phase of Systemic Sclerosis.

Authors:  Satomi Kobayashi; Yasuo Nagafuchi; Hirofumi Shoda; Keishi Fujio
Journal:  Front Immunol       Date:  2022-05-24       Impact factor: 8.786

Review 5.  Clinical Treatment Options in Scleroderma: Recommendations and Comprehensive Review.

Authors:  Ming Zhao; Jiali Wu; Haijing Wu; Amr H Sawalha; Qianjin Lu
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-15       Impact factor: 8.667

Review 6.  Engineered antigen-specific regulatory T cells for autoimmune skin conditions.

Authors:  Zhussipbek Mukhatayev; Yekaterina O Ostapchuk; Deyu Fang; I Caroline Le Poole
Journal:  Autoimmun Rev       Date:  2021-01-18       Impact factor: 17.390

7.  Lymphocyte subsets in the peripheral blood are disturbed in systemic sclerosis patients and can be changed by immunosuppressive medication.

Authors:  Michael Gernert; Hans-Peter Tony; Eva Christina Schwaneck; Ottar Gadeholt; Matthias Fröhlich; Jan Portegys; Patrick-Pascal Strunz; Marc Schmalzing
Journal:  Rheumatol Int       Date:  2021-10-25       Impact factor: 3.580

8.  Sphingosine-1-Phosphate Receptor 5 Modulates Early-Stage Processes during Fibrogenesis in a Mouse Model of Systemic Sclerosis: A Pilot Study.

Authors:  Katrin G Schmidt; Martina Herrero San Juan; Sandra Trautmann; Lucija Berninger; Anja Schwiebs; Florian M Ottenlinger; Dominique Thomas; Frank Zaucke; Josef M Pfeilschifter; Heinfried H Radeke
Journal:  Front Immunol       Date:  2017-09-29       Impact factor: 7.561

9.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. The 2020 Highly morbid forms report.

Authors:  Daniel Wolff; Vedran Radojcic; Robert Lafyatis; Resat Cinar; Rachel K Rosenstein; Edward W Cowen; Guang-Shing Cheng; Ajay Sheshadri; Anne Bergeron; Kirsten M Williams; Jamie L Todd; Takanori Teshima; Geoffrey D E Cuvelier; Ernst Holler; Shannon R McCurdy; Robert R Jenq; Alan M Hanash; David Jacobsohn; Bianca D Santomasso; Sandeep Jain; Yoko Ogawa; Philipp Steven; Zhonghui Katie Luo; Tina Dietrich-Ntoukas; Daniel Saban; Ervina Bilic; Olaf Penack; Linda M Griffith; Meredith Cowden; Paul J Martin; Hildegard T Greinix; Stefanie Sarantopoulos; Gerard Socie; Bruce R Blazar; Joseph Pidala; Carrie L Kitko; Daniel R Couriel; Corey Cutler; Kirk R Schultz; Steven Z Pavletic; Stephanie J Lee; Sophie Paczesny
Journal:  Transplant Cell Ther       Date:  2021-06-10

10.  Propionate supplementation promotes the expansion of peripheral regulatory T-Cells in patients with end-stage renal disease.

Authors:  Fabian Meyer; Felix S Seibert; Mikalai Nienen; Marius Welzel; Daniela Beisser; Frederic Bauer; Benjamin Rohn; Timm H Westhoff; Ulrik Stervbo; Nina Babel
Journal:  J Nephrol       Date:  2020-03-06       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.